Ethan Alt

Assistant Professor

University of North Carolina at Chapel Hill
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (14)

Year:

2026

In clinical trials, it is often of interest to know whether treatment works differently for some groups than others, known as heterogeneity of treatment effect. Such subgroup analysis is complicated to conduct because trials are typically not powered to find subgroups. Furthermore, it is difficult to identify characteristics of patients pertaining to such subgroups. In this article, we propose a semiparametric mixture model to identify subgroups with time-to-event outcomes. Specifically, we assume a proportional hazards model with subgroup-specific piecewise constant baseline hazards, where the subgroup-specific treatment effect is assumed to be the same within each subgroup. The probability of belonging to a certain subgroup is a function of patient prognostic factors. Adopting a Bayesian approach, classification uncertainty is taken into account. We demonstrate the utility of our approach via simulation and an application to data from a real clinical trial in HIV research.

Year:

2025

A common issue in randomized clinical trials (RCTs) is the identification of subgroups and the estimation of their effects. Typically, RCTs are not powered to estimate the effects of subgroups. However, in some circumstances, treatment may work for some groups and not others, and it is of interest to identify these subgroups and estimate their treatment effects. In this paper, we introduce a novel hierarchical grouped horseshoe prior (HGHP) for subgroup identification and estimation. We show via simulation that our proposed approach yields superior positive predictive value and narrower credible intervals compared to other shrinkage priors. We apply our method to a real clinical trial for COVID‐19.

Year:

2025

In clinical trials, it is often valuable to borrow information from external data sources. Unfortunately, when the external data are fully or partially incompatible with the current trial data, type I error rates can be highly inflated under traditional blanket discounting schemes such as power priors, commensurate priors, and meta-analytic predictive priors. However, such inflation of the probability of a false positive can be necessary, as the alternative is to have an underpowered study. For clinical trials with time-to-event (TTE) outcomes, this problem is exacerbated since many observations are censored. In this paper, we develop the latent exchangeability prior for TTE data. We also present a novel framework to borrow information about the treatment effect between groups as well as incorporate information from external controls. Simulation results suggest that, although efficiency gains can be achieved by borrowing information among external controls, operating characteristics in general can be quite poor under a lack of exchangeability. We apply our approach to a real clinical trial in second-line metastatic colorectal cancer.

Year:

2025

Postmarket drug safety database like vaccine adverse event reporting system (VAERS) collect thousands of spontaneous reports annually, with each report recording occurrences of any adverse events (AEs) and use of vaccines. We hope to identify signal vaccine‐AE pairs, for which certain vaccines are statistically associated with certain adverse events (AE), using such data. Thus, the outcomes of interest are multiple AEs, which are binary outcomes and could be correlated because they might share certain latent factors; and the primary covariates are vaccines. Appropriately accounting for the complex correlation among AEs could improve the sensitivity and specificity of identifying signal vaccine‐AE pairs. We propose a two‐step approach in which we first estimate the shared latent factors among AEs using a working multivariate logistic regression model, and then use univariate logistic regression model to examine the vaccine‐AE associations after controlling for the latent factors. Our simulation studies show that this approach outperforms current approaches in terms of sensitivity and specificity. We apply our approach in analyzing VAERS data and report our findings.

Year:

2024

It is becoming increasingly popular to elicit informative priors on the basis of historical data. Popular existing priors, including the power prior, commensurate prior, and robust meta-analytic predictive prior, provide blanket discounting. Thus, if only a subset of participants in the historical data are exchangeable with the current data, these priors may not be appropriate. In order to combat this issue, propensity score approaches have been proposed. However, these approaches are only concerned with the covariate distribution, whereas exchangeability is typically assessed with parameters pertaining to the outcome. In this paper, we introduce the latent exchangeability prior (LEAP), where observations in the historical data are classified into exchangeable and non-exchangeable groups. The LEAP discounts the historical data by identifying the most relevant subjects from the historical data. We compare our proposed approach against alternative approaches in simulations and present a case study using our proposed prior to augment a control arm in a phase 3 clinical trial in plaque psoriasis with an unbalanced randomization scheme.

Year:

2024

The discussions of our paper provide insights into the practical considerations of the latent exchangeability prior while also highlighting further extensions. In this rejoinder, we briefly summarize the discussions and provide comments.

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Collaborators (1)

Joseph G. Ibrahim

University of North Carolina at Chapel Hill

UNITED STATES
View details